185 related articles for article (PubMed ID: 24658181)
1. The paradigm of mutant p53-expressing cancer stem cells and drug resistance.
Shetzer Y; Solomon H; Koifman G; Molchadsky A; Horesh S; Rotter V
Carcinogenesis; 2014 Jun; 35(6):1196-208. PubMed ID: 24658181
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
Chan KT; Lung ML
Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724
[TBL] [Abstract][Full Text] [Related]
3. Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2.
Ozaki T; Nakamura M; Shimozato O
Biomolecules; 2015 Oct; 5(4):2854-76. PubMed ID: 26512706
[TBL] [Abstract][Full Text] [Related]
4. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.
Masciarelli S; Fontemaggi G; Di Agostino S; Donzelli S; Carcarino E; Strano S; Blandino G
Oncogene; 2014 Mar; 33(12):1601-8. PubMed ID: 23584479
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.
Solomon H; Dinowitz N; Pateras IS; Cooks T; Shetzer Y; Molchadsky A; Charni M; Rabani S; Koifman G; Tarcic O; Porat Z; Kogan-Sakin I; Goldfinger N; Oren M; Harris CC; Gorgoulis VG; Rotter V
Oncogene; 2018 Mar; 37(12):1669-1684. PubMed ID: 29343849
[TBL] [Abstract][Full Text] [Related]
6. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
8. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance.
Park EY; Chang E; Lee EJ; Lee HW; Kang HG; Chun KH; Woo YM; Kong HK; Ko JY; Suzuki H; Song E; Park JH
Cancer Res; 2014 Dec; 74(24):7573-82. PubMed ID: 25368020
[TBL] [Abstract][Full Text] [Related]
9. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil.
Pugacheva EN; Ivanov AV; Kravchenko JE; Kopnin BP; Levine AJ; Chumakov PM
Oncogene; 2002 Jul; 21(30):4595-600. PubMed ID: 12096336
[TBL] [Abstract][Full Text] [Related]
10. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
[TBL] [Abstract][Full Text] [Related]
12. p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.
Rodriguez-Ramirez C; Nör JE
Crit Rev Oncog; 2018; 23(3-4):173-187. PubMed ID: 30311573
[TBL] [Abstract][Full Text] [Related]
13. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.
Shetzer Y; Molchadsky A; Rotter V
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27235476
[TBL] [Abstract][Full Text] [Related]
15. Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness.
Olivos DJ; Mayo LD
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27898034
[TBL] [Abstract][Full Text] [Related]
16. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
17. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
19. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair.
Barckhausen C; Roos WP; Naumann SC; Kaina B
Oncogene; 2014 Apr; 33(15):1964-74. PubMed ID: 23604128
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional activities of mutant p53: when mutations are more than a loss.
Kim E; Deppert W
J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
